New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:04 EDTNNVCNanoViricides reports R&D Lab, cGMP facility near construction completion
NanoViricides reported that construction of the modern R&D Lab and cGMP Clinical Production facility in Shelton, Connecticut, is nearing completion on schedule. The company reports that the R&D lab section of the facility is nearing completion, slightly ahead of schedule. In addition, construction of the cGMP Clean Room Production Suite is expected to be completed in March, 2014, on schedule, and shortly thereafter, the project will enter facility testing and validation phase. After construction is complete, the facility, and particularly the cGMP Clean Room Suites will undergo facility testing and validation to ascertain that the facility satisfies the requirements. After validation, the company plans to occupy the new facility while keeping the current facility active to minimize impact on the multiple nanoviricides® drug development projects. The company intends to first start production of FluCide in the cGMP section, set up appropriate cGMP operation for this production, produce multiple batches of FluCide under cGMP conditions, and demonstrate equivalence of the batches produced, in preparation for human clinical trials.
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
09:14 EDTNNVCNanoViricides provides quarterly report
NanoViricides filed its quarterly report with the SEC estimating that it now has approximately $36.4M of current assets plus restricted cash as of December 31, 2014. The company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter. The company reported that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate. The company's anti-Ebola nanoviricide drug candidates have been sent for testing at a prestigious BSL4 facility in the .S. The company has the ability to produce sufficient quantities of a successful drug candidate for potential field use. The company estimates that the cash in hand is sufficient to enable initial human clinical trials of injectable FluCide drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use